Antonio J. Gonzalez-Martin

Corrigendum to "SUROVA Study: Global Real-World Treatment Strategies And Mortality Risk Prediction In Advanced Ovarian Cancer" [International Journal of Gynecological Cancer 36 (2026) 102688].

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 30, 2026

Corrigendum to "Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners" [International Journal of Gynecological Cancer 36 (2026) 104753].

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: July 02, 2026

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Journal: JAMA oncology

Published: June 25, 2026

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 19, 2026

Early death and early relapse in advanced ovarian cancer: distinct clinical phenotypes in the International SUROVA cohort.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 19, 2026

Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 28, 2026

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Journal: Gynecologic oncology

Published: April 12, 2026

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

Journal: The Lancet. Oncology

Published: March 04, 2026

HPV-related cancer prevention in Spain: progress and remaining challenges in vaccination, screening, and surveillance.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: February 06, 2026

Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Journal: Journal of gynecologic oncology

Published: January 19, 2026

Corrigendum to "SUROVA Study: Global Real-World Treatment Strategies And Mortality Risk Prediction In Advanced Ovarian Cancer" [International Journal of Gynecological Cancer 36 (2026) 102688].

Corrigendum to "SUROVA Study: Global Real-World Treatment Strategies And Mortality Risk Prediction In Advanced Ovarian Cancer" [International Journal of Gynecological Cancer 36 (2026) 102688].

Corrigendum to "Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners" [International Journal of Gynecological Cancer 36 (2026) 104753].

Corrigendum to "Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners" [International Journal of Gynecological Cancer 36 (2026) 104753].

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Early death and early relapse in advanced ovarian cancer: distinct clinical phenotypes in the International SUROVA cohort.

Early death and early relapse in advanced ovarian cancer: distinct clinical phenotypes in the International SUROVA cohort.

Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners.

Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners.

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

HPV-related cancer prevention in Spain: progress and remaining challenges in vaccination, screening, and surveillance.

HPV-related cancer prevention in Spain: progress and remaining challenges in vaccination, screening, and surveillance.

Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Real-world evidence to accelerate knowledge in gynecologic oncology.

Real-world evidence to accelerate knowledge in gynecologic oncology.

Assessing platinum response in first-line advanced ovarian cancer: clinical implications and future directions.

Assessing platinum response in first-line advanced ovarian cancer: clinical implications and future directions.